A major asthma discovery by a researcher at the Institute has been licensed by MedImmune, a biotechnology company and wholly owned subsidiary of AstraZeneca PLC [REF].
A discovery by scientists at the Institute has entered pharmaceutical research for use in the creation of a potential new antibody therapy for ulcerative colitis and Crohn's disease.